ERBB2 and breast cancer: In conclusion, baseline neutrophil count, HER2 status, and clinical response jointly predict apCR post‐NAT in cN+ breast cancer, and the proposed immunoscore nomogram offers a practical tool to guide axillary de‐escalation and optimize surgical decision‐making.